Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis

2017 ◽  
Vol 36 (1) ◽  
pp. 136-143 ◽  
Author(s):  
Alessandro Broccoli ◽  
Lisa Argnani ◽  
Vittorio Stefoni ◽  
Letizia Gandolfi ◽  
Pier Luigi Zinzani
Keyword(s):  
Efficacy And Safety ◽  
Lymphoid Neoplasms ◽  
Epoetin Alpha

Efficacy and safety of biosimilar epoetin alpha in treated patients with multiple myeloma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e18563-e18563
Author(s):  
Giusy Antolino ◽  
Alessandro Moscetti ◽  
Francesca Saltarelli ◽  
Bruno Monarca ◽  
Federica Resci ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Safety Data ◽  
Supportive Therapy ◽  
Pharmaceutical Products ◽  
Steady Increase ◽  
Efficacy And Safety ◽  
Duration Of Treatment ◽  
Biologic Drugs ◽  
Biosimilar Pharmaceuticals ◽  
Epoetin Alpha

e18563 Background: The biologic drugs are pharmaceutical products derived from living organisms through biotechnology. For some of the biotech drugs patent coverage is now decayed. This has allowed other companies to produce, at lower costs, similar products called biosimilar pharmaceuticals. Among the first biosimilar products marketed there were two growth factors, epoetin alpha and filgrastim. Methods: We retrospectively analyzed 15 chemo-treated patients with Multiple Myeloma (MM) referred to UOS Diagnosi e Cura delle Discrasie Plasmacellulari e delle Amiloidosi of Sant’Andrea Hospital in Rome, who were treated with biosimilar epoetin alpha between November 2010 and November 2011. In particular, 6 males and 9 females (median age 70 years) had started therapy with subcutaneous biosimilar epoetin alpha 40,000 IU weekly for haemoglobin level below 10 g/dl. In these patients, we evaluated the Hb levels before treatment, after 4 weeks and, in those who continued therapy, after 8 weeks from the drug administration start. Results: In all cases there was a significant and steady increase of Hb values: we observed an increase of 1 g/dl after 4 weeks in 80% of patients. In 5 of 11 patients the data are not available at 8 weeks because it was observed a so quick increase in Hb values as to cause discontinuation of treatment; in 100% of the remaining patients we observed an increase ≥2 g/dl after 8 weeks. None of patients needed supportive therapy with red blood cells transfusion. Although the duration of treatment in our patients was limited, we did not observe any adverse event in the short and medium term by the administration. Conclusions: The results reported do not fall in a comparative study and our initial data are still limited, however in our analysis biosimilar epoetin alpha was effective in increasing Hb values in MM patients against lower costs. It should be emphasized that this growth factor has been used in overtreated patients with impaired bone marrow reserve. In our analysis biosimilar epoetin alpha has shown efficacy and safety data to suggest the possibility of their use in alternative to biotech generators.

A first approach to compare efficacy and safety of lepirudin and danaparoid in patients with heparin-induced thrombocytopenia (HIT)

2000 ◽  
Vol 10 (4) ◽  
pp. 325-325
Author(s):  
B. Farner ◽  
P. Eichler ◽  
H. Kroll ◽  
G. Urban ◽  
A. Greinacher
Keyword(s):  
Efficacy And Safety ◽  
Heparin Induced Thrombocytopenia

Efficacy and Safety of a Novel Botulinum Toxin Topical Gel

2012 ◽  
Vol 2012 ◽  
pp. 276-277
Author(s):  
M.H. Gold
Keyword(s):  
Botulinum Toxin ◽  
Efficacy And Safety ◽  
Topical Gel

The efficacy and safety of argon plasma coagulation in the management of polyps remnants in stomach and colon

2001 ◽  
Vol 120 (5) ◽  
pp. A258-A258
Author(s):  
B NENEMAN ◽  
G BOMBSKI ◽  
E MALECKAPANAS
Keyword(s):  
Argon Plasma Coagulation ◽  
Argon Plasma ◽  
Efficacy And Safety ◽  
Plasma Coagulation

The efficacy and safety of long-term administration of alpha-interferon and lamivudine in patients with chronic hepatitits B

2001 ◽  
Vol 120 (5) ◽  
pp. A572-A572
Author(s):  
F JABOLI ◽  
E RODA ◽  
C FABBRI ◽  
S MARCHETTO ◽  
F FERRARA ◽  
...  
Keyword(s):  
Alpha Interferon ◽  
Efficacy And Safety ◽  
Term Administration

1560: The Efficacy and Safety of Dose Escalating Methods in Patients with Benign Prostatic Hyperplasia and Hypertension

2007 ◽  
Vol 177 (4S) ◽  
pp. 515-515
Author(s):  
In Rae Cho ◽  
JonGgu Kim ◽  
KeonCheol Lee
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Efficacy And Safety ◽  
Dose Escalating
Sign in / Sign up

Export Citation Format

Share Document